Cidara Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDTX research report →
Companywww.cidara.com
Cidara Therapeutics, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
- CEO
- Jeffrey L. Stein
- IPO
- 2015
- Employees
- 38
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $5.61B
- P/E
- -18.63
- P/S
- 0.00
- P/B
- 8.15
- EV/EBITDA
- -28.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -60.15%
- ROIC
- -46.06%
Growth & Income
- Revenue
- $1.27M · -94.52%
- Net Income
- $-169,827,000 · -640.60%
- EPS
- $-26.75 · -409.52%
- Op Income
- $-176,102,000
- FCF YoY
- -670.21%
Performance & Tape
- 52W High
- $221.42
- 52W Low
- $15.22
- 50D MA
- $187.66
- 200D MA
- $84.67
- Beta
- 1.53
- Avg Volume
- 1.37M
Get TickerSpark's AI analysis on CDTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 7, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,286,786 |
| Jan 7, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 89,956 |
| Jan 7, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 4,652,309 |
| Jan 7, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 5,079 |
| Jan 7, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,286,786 |
| Jan 7, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 22,200 |
| Jan 7, 26 | Resnick Joshua | sell | 5,079 |
| Jan 7, 26 | Resnick Joshua | sell | 22,200 |
| Jan 7, 26 | Spencer Ryan | sell | 2,125 |
| Jan 7, 26 | Spencer Ryan | sell | 11,100 |
Our CDTX Coverage
We haven't published any research on CDTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CDTX Report →